Moreover, combination treatment of BJIKT and anti-PD-L1 antibody showed more meaningful results in the immunocompetent model than in the poorly immunogenic model, suggesting that the role of BJIKT may be significantly associated with the immune response in the tumor microenvironment. The gene discussed is CD274; the disease is neoplasm.